Progressive Multiple Sclerosis Pms clinical trials

Explore recruiting progressive multiple sclerosis pms clinical trials.

Recruiting progressive multiple sclerosis pms studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Progressive Multiple Sclerosis Pms trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis

Sweden, Croatia, Norway, Slovakia, France, Lithuania +17 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis

Denmark, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis

Netherlands, Germany, Denmark, Poland, Czechia, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, multi-center, phase I/II study to assess safety, disease progression, and cellular kinetics following YTB323 administration in participants with non-active Progressive Multiple Sclerosis (PMS)

Spain, France, Italy, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

P2-IMU-838-PMS - Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis (Calliper)

Germany, Czechia, Netherlands, Bulgaria, Romania, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2)

Germany, Belgium, France, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

Progressive Multiple Sclerosis Pms trials by city

Progressive Multiple Sclerosis Pms in Toronto Progressive Multiple Sclerosis Pms in Vancouver Progressive Multiple Sclerosis Pms in Montreal Progressive Multiple Sclerosis Pms in Calgary Progressive Multiple Sclerosis Pms in Edmonton Progressive Multiple Sclerosis Pms in Ottawa Progressive Multiple Sclerosis Pms in Winnipeg Progressive Multiple Sclerosis Pms in Quebec City Progressive Multiple Sclerosis Pms in Hamilton Progressive Multiple Sclerosis Pms in Kitchener Progressive Multiple Sclerosis Pms in London Progressive Multiple Sclerosis Pms in Halifax Progressive Multiple Sclerosis Pms in New York Progressive Multiple Sclerosis Pms in Los Angeles Progressive Multiple Sclerosis Pms in Chicago Progressive Multiple Sclerosis Pms in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease